|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:PMDA
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AX25
|
|
gptkbp:brand
|
gptkb:Xofluza
|
|
gptkbp:CASNumber
|
1985606-14-1
|
|
gptkbp:chemicalFormula
|
C27H23F2N3O7
|
|
gptkbp:contraindication
|
hypersensitivity
pregnancy (caution)
|
|
gptkbp:developer
|
gptkb:Roche
gptkb:Shionogi
|
|
gptkbp:drugClass
|
endonuclease inhibitor
|
|
gptkbp:eliminationHalfLife
|
79.1 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
gptkb:tablet
granules
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
baloxavir marboxil
|
|
gptkbp:indication
|
post-exposure prophylaxis of influenza
acute uncomplicated influenza
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
cap-dependent endonuclease inhibitor
|
|
gptkbp:metabolism
|
liver (UGT1A3, CYP3A4)
|
|
gptkbp:molecularWeight
|
571.5 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prodrugOf
|
gptkb:baloxavir_acid
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bronchitis
nausea
diarrhea
headache
|
|
gptkbp:target
|
gptkb:influenza_virus_polymerase_acidic_protein
|
|
gptkbp:usedFor
|
influenza
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Influenza_A
gptkb:Influenza_virus
gptkb:influenza_B_virus
gptkb:Influenza_A_virus
gptkb:Seasonal_influenza
|
|
gptkbp:bfsLayer
|
5
|